Otsuka’s Samska gets advisory committee review
FDA's Cardiovascular and Renal Drugs Advisory Committee will meet June 25 to evaluate Otsuka's hyponatremia drug Samska (tolvaptan) for patients with hypervolemic and euvolemic hyponatremia. The committee is concerned particularly with the change in sodium level as basis for drug approval. If approved, the selective V2-vasopressin receptor antagonist would be the first oral product in the vasopressin antagonist market. Otsuka is seeking a standard review of tolvaptan, putting the user fee goal date at Aug. 23
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.